Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Spruce Biosciences, Inc. (SPRB)

1.17   0.01 (0.86%) 12-05 16:00
Open: 1.13 Pre. Close: 1.16
High: 1.2 Low: 1.1
Volume: 49,453 Market Cap: 28(M)

Technical analysis

as of: 2022-12-06 9:22:10 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.56     One year: 1.82
Support: Support1: 1.12    Support2: 0.99
Resistance: Resistance1: 1.34    Resistance2: 1.56
Pivot: 1.1
Moving Average: MA(5): 1.13     MA(20): 1.09
MA(100): 1.54     MA(250): 1.95
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 51.1     %D(3): 44.7
RSI: RSI(14): 53.3
52-week: High: 5.8  Low: 0.96
Average Vol(K): 3-Month: 53 (K)  10-Days: 43 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SPRB ] has closed below upper band by 16.7%. Bollinger Bands are 50.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.2 - 1.2 1.2 - 1.21
Low: 1.09 - 1.09 1.09 - 1.1
Close: 1.16 - 1.17 1.17 - 1.18

Company Description

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Headline News

Wed, 23 Nov 2022
Does Spruce Biosciences Inc (SPRB) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver

Thu, 17 Nov 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace

Wed, 16 Nov 2022
Will Spruce Biosciences Inc (SPRB) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Wed, 16 Nov 2022
Target's Q3 Earnings Miss Drags Premarket Lower Ahead of Economic Reports - InvestorsObserver

Thu, 10 Nov 2022
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates - Yahoo Finance

Thu, 03 Nov 2022
Spruce Biosciences, Inc. (SPRB) Stock Price Today, Quote & News - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 24 (M)
Shares Float 6 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 85.2 (%)
Shares Short 267 (K)
Shares Short P.Month 61 (K)

Stock Financials

EPS -1.89
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.32
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -24.1
Return on Equity (ttm) -44.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.88
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.63
PEG Ratio 0
Price to Book value 0.35
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.